Placebo to match Enpatoran
Sponsors
Merck Healthcare KGaA
Conditions
Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Not yet recruitingCTIS2025-524855-30-00
Target: 15Updated: 2026-06-30
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Not yet recruitingCTIS2025-523871-44-00
Target: 16Updated: 2026-06-30